Erythroid-transdifferentiated myeloid cells promote portal vein tumor thrombus in hepatocellular carcinoma

被引:1
|
作者
Zhu, Wei-Hang [1 ,2 ]
Chen, Jie [1 ,2 ]
Huang, Run-Kai [1 ,2 ]
Zhang, Yuan [3 ]
Huang, Ze-Xuan [2 ,4 ]
Pang, Xiu-Qing [2 ,4 ]
Hu, Bo [5 ]
Yang, Yang [6 ,7 ,8 ]
Li, Xing [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Med Oncol, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Key Lab Liver Dis Res, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Obstet, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Lab Med, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepat Surg, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 3, Liver Transplantat Ctr, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Prov Key Lab Liver Dis Res, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
来源
THERANOSTICS | 2023年 / 13卷 / 13期
基金
中国国家自然科学基金;
关键词
Portal vein tumor thrombus; Coagulation; CD45(+) EPC; Hepatocellular carcinoma; Vascular endothelial cells; SUPPRESSOR-CELLS; FIBRINOGEN;
D O I
10.7150/thno.82907
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Rationale: Hepatocellular carcinoma (HCC) is primarily characterized by a high incidence of vascular invasion. However, the specific mechanism underlying portal vein tumor thrombus (PVTT) in HCC remains unclear. As a consequence of myeloid cell developmental arrest, CD71(+) erythroid progenitor cells (EPCs) and myeloid-derived suppressor cells play important roles in HCC; however, their roles in PVTT remain unclear. Methods: The role of CD71(+) EPCs in the HCC tumor microenvironment (TME) was evaluated via morphological, RNA- sequencing, enzyme-linked immunosorbent assay, and flow cytometric analyses. Co-culture techniques were employed to assess the CD45(+) EPCs and their vascular compromising effect. Additionally, the PVTT-promoting function of CD45(+) EPCs was explored in vivo in a murine model. Results: The CD45(+) EPCs in HCC tissues exhibited increased myeloid cell features, including morphology, surface markers, transforming growth factor ( TGF)-beta generation, and gene expression, compared with those in circulation. Hence, a large proportion of CD45(+)EPCs, particularly those in TMEs, comprise erythroid-transdifferentiated myeloid cells (EDMCs). Additionally, the expression of C-C chemokine receptor type 2 (CCR2) mRNA was upregulated in CD45(+)EPCs within the TME. Tumor macrophages from HCC tissues induced substantial migration of CD45(+)EPCs in a dose-dependent manner. Meanwhile, results from immunofluorescence analyses revealed that these two cell types are positively associated in the TME and circulation. That is, EDMCs are chemoattracted by HCC macrophages mainly via CCR2 from CD45(+) EPCs in the circulation. Additionally, the expressions of FX, FVII, FGB, C4b, CFB, and CFH were elevated in CD45(+)EPCs within the TME compared with those in the spleen. The CD45(+)EPCs from the HCC TME promoted vessel endothelial cell migration and compromised tube formation through TGF-beta and FGB, respectively. Additionally, CD45(+)EPCs from the TME induced HCC cell migration. HCC macrophage-induced CD45(+)EPCs to exhibit higher levels of FX, FVII, FGB, and TGF-beta. Meanwhile, upregulation of CCAAT/enhancer binding protein beta expression induced FGB and TGF-beta generation in CD45(+)EPCs in the TME. WTAP, a major RNA m(6)A writer, stabilized FX and FVII mRNA and enhanced their nuclear export in CD45(+)EPCs from the TME. CD45(+)EPCs from the TME were positively associated with PVTT and poor prognosis. Splenectomy reduced the level of CD45(+)EPCs in the circulation and TME, as well as the incidence of microvascular invasion. The incidence of microvascular invasion increased following the transfer of HCC tissue CD45(+)EPCs to splenectomized HCC-bearing mice. Conclusions: The CD45(+)EPCs enriched in the HCC microenvironment are EDMCs, which are induced by HCC macrophages to migrate from the circulation to the TME. Subsequently, EDMCs promote PVTT by compromising the blood vessel endothelium, aggravating coagulation, and promoting HCC cell migration.
引用
收藏
页码:4316 / 4332
页数:17
相关论文
共 50 条
  • [31] Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus
    Sakamoto, Kazuhiko
    Nagano, Hiroaki
    HEPATOLOGY RESEARCH, 2017, 47 (10) : 957 - 962
  • [32] Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus
    Hata, M
    Tokuuye, K
    Sugahara, S
    Kagei, K
    Igaki, H
    Hashimoto, T
    Ohara, K
    Matsuzaki, Y
    Tanaka, N
    Akine, Y
    CANCER, 2005, 104 (04) : 794 - 801
  • [33] Hepatocellular Carcinoma with Portal Vein Tumor Thrombus versus Hepatocellular Carcinoma with Biliary Tumor Thrombus: Better or Worse Prognoses? [Response to Letter]
    Yang, Xin
    Zhu, Ying
    Zhao, Xia
    Li, Jian-Hua
    Xu, Da
    Jia, Hu-Liang
    Zhang, Jubo
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 1323 - 1324
  • [34] Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein
    Cheng Shuqun
    Wu Mengchao
    Chen Han
    Shen Feng
    Yang Jiahe
    Ding Guanghui
    Cong Wenming
    Wang Peijun
    Zhao Yuxiang
    HEPATO-GASTROENTEROLOGY, 2007, 54 (74) : 499 - 502
  • [35] HEPATOCELLULAR CARCINOMA WITH TUMOR THROMBUS EXTENDING FROM THE PORTAL VEIN TO THE RIGHT ATRIUM
    Numan, Laith
    Kalot, Mohamad
    Husainat, Nedaa M.
    Abughanimeh, Omar
    JOURNAL OF INVESTIGATIVE MEDICINE, 2019, 67 (05) : 887 - 888
  • [36] The potential of plasma thrombomodulin as a biomarker of portal vein tumor thrombus in hepatocellular carcinoma
    Zhou, J
    Tang, ZY
    Fan, J
    Wu, ZQ
    Ji, Y
    Ye, SL
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2001, 127 (09) : 559 - 564
  • [37] Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus
    Shu-You Peng
    Xu-An Wang
    Cong-Yun Huang
    Jiang-Tao Li
    De-Fei Hong
    Yi-Fang Wang
    Bin Xu
    World Journal of Gastroenterology, 2018, 24 (40) : 4527 - 4535
  • [38] Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus
    Minagawa, M
    Makuuchi, M
    Takayama, T
    Ohtomo, K
    ANNALS OF SURGERY, 2001, 233 (03) : 379 - 384
  • [39] Hepatocellular Carcinoma with Tumor Thrombus Extending from the Portal Vein to the Right Atrium
    Numan, Laith
    Asif, Samia
    Abughanimeh, Omar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (05)
  • [40] A stable and reliable animal model for hepatocellular carcinoma with portal vein tumor thrombus
    Chai, Zong-Tao
    Chen, Zhen-Hua
    Zhang, Xiu-Ping
    Feng, Jin-Kai
    Liu, Zong-Han
    Cheng, Shu-Qun
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2022, 21 (01) : 90 - 93